Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Bass

Showing results (361-370 of 399) with videos related to

Pageof 40
Sort By:
Cardiovascular Revascularization Medicine : Including Molecular Interventions|April 22, 2023
Effect of High-Intensity Statin Therapy on Atherosclerosis (IBIS-4): Manual Versus Automated Methods of IVUS AnalysisRonald D Bass, Héctor M García-García, Yasushi Ueki, et al.
Critical Care Explorations|April 4, 2022
Six-Month Impairment in Cognition, Mental Health, and Physical Function Following COVID-19-Associated Respiratory FailureJason H Maley, Danielle K Sandsmark, Alison Trainor, et al.
Journal of Neurology|June 26, 2020
Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223Brian Steingo, Yaser Al Malik, Ann D Bass, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 9, 2021
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing dataAlasdair J Coles, Joanne L Jones, Patrick Vermersch, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 21, 2019
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and managementAdam Cuker, Ann D Bass, Congor Nadj, et al.
Neurology. Clinical Practice|August 26, 2024
The Recovery of Consciousness via Evidence-Based Medicine and Research (RECOVER) Program: A Paradigm for Advancing NeuroprognosticationDavid Fischer, Benjamin S Abella, Geoffrey D Bass, et al.
Therapeutic Advances in Neurological Disorders|May 26, 2021
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trialAlasdair J Coles, Douglas L Arnold, Ann D Bass, et al.
Multiple Sclerosis and Related Disorders|January 21, 2021
Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 yearsAnn D Bass, Rafael Arroyo, Aaron L Boster, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2019
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studiesGiancarlo Comi, Raed Alroughani, Aaron L Boster, et al.
CNS Drugs|July 26, 2020
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension StudyTjalf Ziemssen, Ann D Bass, Regina Berkovich, et al.
Pageof 40

Showing results (361-370 of 399) with videos related to

Sort By:
Pageof 40
Cardiovascular Revascularization Medicine : Including Molecular Interventions|April 22, 2023
Effect of High-Intensity Statin Therapy on Atherosclerosis (IBIS-4): Manual Versus Automated Methods of IVUS AnalysisRonald D Bass, Héctor M García-García, Yasushi Ueki, et al.
Critical Care Explorations|April 4, 2022
Six-Month Impairment in Cognition, Mental Health, and Physical Function Following COVID-19-Associated Respiratory FailureJason H Maley, Danielle K Sandsmark, Alison Trainor, et al.
Journal of Neurology|June 26, 2020
Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223Brian Steingo, Yaser Al Malik, Ann D Bass, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 9, 2021
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing dataAlasdair J Coles, Joanne L Jones, Patrick Vermersch, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 21, 2019
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and managementAdam Cuker, Ann D Bass, Congor Nadj, et al.
Neurology. Clinical Practice|August 26, 2024
The Recovery of Consciousness via Evidence-Based Medicine and Research (RECOVER) Program: A Paradigm for Advancing NeuroprognosticationDavid Fischer, Benjamin S Abella, Geoffrey D Bass, et al.
Therapeutic Advances in Neurological Disorders|May 26, 2021
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trialAlasdair J Coles, Douglas L Arnold, Ann D Bass, et al.
Multiple Sclerosis and Related Disorders|January 21, 2021
Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 yearsAnn D Bass, Rafael Arroyo, Aaron L Boster, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2019
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studiesGiancarlo Comi, Raed Alroughani, Aaron L Boster, et al.
CNS Drugs|July 26, 2020
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension StudyTjalf Ziemssen, Ann D Bass, Regina Berkovich, et al.
Pageof 40